CORDIS
EU research results

CORDIS

English EN

IMPROVED RETROGRADE LENTIVIRAL VECTORS FOR GENE THERAPY IN MOTOR NEURON DISEASES

Project information

Grant agreement ID: 233147

Status

Closed project

  • Start date

    1 April 2009

  • End date

    31 August 2014

Funded under:

FP7-IDEAS-ERC

  • Overall budget:

    € 2 000 000

  • EU contribution

    € 2 000 000

Hosted by:

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

Objective

Lentiviral vectors can be targeted to specific cell types by varying the envelope proteins, a process called pseudotyping. The rabies-G pseudotyped lentivectors are useful for distal targeting of neurons because they are retrogradely transported to the nucleus where they integrate and express the transgene, as first demonstrated by us. Motor neuron (MN) diseases are incurable neurodegenerative diseases causing progressive paralysis and premature death. Most amyotrophic lateral sclerosis (ALS) cases are sporadic, but there are rare inherited forms one of which being due to mutations in the superoxide dismutase (SOD1) gene. Spinal muscular atrophy (SMA) is the second commonest genetic disease affecting children and is due to mutations in the survival motor neuron (SMN1) gene. In mouse models for ALS (SOD1 mutant mouse) or SMA (SMNDelta7 mouse) when we delivered in various muscle groups rabies-G pseudotyped lentiviral vectors expressing either vascular endothelial growth factor or short interfering RNA targeted to a mutated SOD1 gene or the normal SMN1 gene we corrected motor defects and extended survival. Despite these successes, experiments with rabies-G pseudotyped vectors in non-human primates have failed to give good efficiency of transduction of MNs so as to translate this approach to the clinic. Also SMN-1 targeted replacement produced only a marginal increase in survival despite sparing MNs. In this grant we propose: 1) To investigate the molecular pathway of retrograde transport of the rabies-G lentiviral vectors. This might allow us to increase the efficacy of gene transfer with these vector systems. 2) To design novel lentiviral vectors with tropism to the neuromuscular junction (NMJ) so as to try to increase the efficiency/specificity of gene transfer to MNs. 3) To utilise the new NMJ-targeted lentiviral vector derived in (2) to simultaneously deliver several neuroprotective proteins to MNs and test its efficacy in animal models of ALS and SMA.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Principal Investigator

Nicholas Mazarakis (Prof.)

Host institution

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Address

South Kensington Campus Exhibition Road
Sw7 2az London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 000 000

Principal Investigator

Nicholas Mazarakis (Prof.)

Administrative Contact

Tatjana Palalic (Ms.)

Beneficiaries (1)

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 2 000 000

Project information

Grant agreement ID: 233147

Status

Closed project

  • Start date

    1 April 2009

  • End date

    31 August 2014

Funded under:

FP7-IDEAS-ERC

  • Overall budget:

    € 2 000 000

  • EU contribution

    € 2 000 000

Hosted by:

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom